Member Info for crumbs

And not just titles ... can have a little read to try understand these latest abstracts
https://static1.squarespace.com/static/56dee71e555986fb3ae583e2/t/5d8939d1fd3ef815d5f998f0/1569274327669/Abstract+book+FINAL.pdf
Cheers TF

Oh nice, the titles are out, that is a whole lot of science there the understanding of moditope, in particular, grows and grows and all to be presented right under Sahin and Mellman's noses by the talents of team scancell science.... I too am not sure we will get an RNS for the event however with so many new abstracts to be presented by not just Lindy it is possible... as I think we all agree 6 abstracts is impressive .... As for what may come from of it well that is down to who is paying attention :) if Sahin sees Mellman make a b line for Lindy and gets all jealous things we want to happen could get a move on lol

It is a kinase inhibitor... seems to be an effective one...
An interesting article on it is here:
https://www.evaluate.com/vantage/articles/news/pricing/bayer-wants-top-dollar-larotrectinib

6... Atabani ,Brentville, Chua,Cook , Durrant and Paston

Wow, can see another - Katherine Cook... so that is at least 6 abstracts.. I do not think we have ever done an event like this before!... wonder what all the abstracts can be about... just shows how much science is going on.... excited to get to see the posters

Ooh there are more Abstracts... me and boom got it to 4 already... but your right Sam Paston now has one too... got to be on TCR that surely..... Team scancell science there in force!

His PDA actuals will condemn him :)

Where are you?

Close but not quite there... your lead is safe :) seems no one else is interested today though ... calm before a storm of course!

Yeah a bit bigger than usual lol... and probably the last for a while... hoping some newsflow comes through to start the assault on 10p again :) and then onwards into the excitement of what next year ought to bring

And that'll be it over on NEX

We could be in for a mighty crumbs sized buy today :)

Yes, great spot, thanks boom, things are getting busy at scancell... I think they missed Panama need not apply :)

MaB facts:

'Global monoclonal antibody market has been expanding over the recent years, with its size posting USD115.2 billion in 2018, a year-on-year increase of 11%. As of April 2019, there have been 182 monoclonal antibody drugs undergoing Phase III clinical trials worldwide. It is expected that many a monoclonal antibody drug will be approved and rolled out into the market in the forthcoming years, favoring a ballooning market size to USD240.2 billion in 2025.

Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.

Monoclonal antibody drugs have been maturing from a research target to an improved technology, from clinical research to commercialization over the past three decades. In recent years, the number of monoclonal antibody drugs approved for launch proliferated, with 78 approved and available on the market as of May 2018.

In 2017, 7 of 10 best-selling drugs worldwide were monoclonal antibody drugs, the fastest growing segment in global bio-pharmaceutical market. In Merck's case, the sales of its Keytruda which was launched in 2014, hit RMB7.171 billion in 2018 alone.

The world's monoclonal antibody market is now almost carved up by Roche, Johnson & Johnson, Merck, Novartis, AbbVie and Amgen. In 2018, the global top eight monoclonal antibody drugs by sales, collectively USD64,052 million, were HuMiRA, Herceptin, Avastin, Keytruda, Rituxan, Remicade, Stelara and ENBREL, with a combined 55.6% share in global market.'

Yes it will indeed be interesting to see what the US NASDAQ values BioNtech at and how their shares fair I'm sure they will have a better market ride than our AIM one lol..... worth remembering this about BioNtech and TCRs.... they already have Lilly paying them money to come up with a TCR product since 2015.... so far no TCR product....

'Eli Lilly and BioNTech AG have signed a research pact to discover novel cancer immunotherapies, seeking to use the body's own immune system to attack cancer cells and create possible new treatment options.

The companies plan to work together to identify and validate new tumour targets and their corresponding T cell receptors (TCRs) in one or more types of cancer, which may then be engineered and developed into “potent and selective” therapies.

The German biotech will bank a $30 million signing fee, but stands to receive an extra $300 million for each potential new medicine in development, regulatory and commercial milestones.

Lilly has also agreed to make a $30 million equity investment in BioNTech’s subsidiary Cell & Gene Therapies GmbH, which specialises in TCR and chimeric antigen receptor immunotherapies, but further terms were kept under wraps.'

Worth a read:
https://seekingalpha.com/article/4291794-biontech-begins-u-s-ipo-effort

'to complete our ongoing and currently planned clinical trials for our FixVac product candidates BNT111, BNT113 and BNT114, as well as to fund our portion of the research and development expenses for each of the following: RO7198457 (BNT122), which is being developed in collaboration with Genentech, SAR441000 (BNT131), which is being developed in collaboration with Sanofi, and GEN1046 (BNT311) and GEN1042 (BNT312), which are being developed in collaboration with Genmab;

to advance additional product candidates through Phase 1 clinical trials, including product candidates from our CAR T, RiboMabs, RiboCytokines and TCR platforms in oncology, and our infectious disease immunotherapy and rare disease protein replacement therapy platforms outside oncology;

to advance additional preclinical product candidates, develop additional product candidates leveraging our current therapeutic platforms and fund the further development of our core technologies; and

to fund the further expansion of our manufacturing and laboratory capacity and the continued development of our infrastructure.

We expect to use the remainder of any net proceeds from this offering, as well as our existing cash and cash equivalents, for general corporate purposes.'

From PDF:
Modi-2: homocitrullination of lysine residues – PCT filed 9-9-19
Screened 18 peptides using new algorithm
18 stimulated T cell responses
5 gave strong anti-tumour responses

Yeah, Ivy, I think its something like that, just can't make it out clearly enough to get all the words Lindy has obviously worked really hard on this collab and I am not betting against her on it I think it will get nailed... like I said the other day she got Sam Paston onboard and to move from the so-called UK biotech Immunocore where she was a long-termer and contributed to the building of their IP.... I think she was excited at the prospect and potential.... loads we do not know yet for instance what cancer target is BioNtech particularly wanting to target but if I'm right in what Cliff said they have a choice of 33 to choose from

They get through a lot of info fast so it is easy to miss the odd gem no doubt even if you were sat there... If bob is around I wonder did he ask CH/JC in post AGM chat about the last time they met and they inferred there was going to be a further BioNtech announcement which subsequently did not appear

Sounds about right to me John lol .... I wish I could fully make out Lindy's part of the Q&A TCR answer ...I know she mentions cd4 cells and citrullinated epitopes and BioNtech being also interested in vaccines as are other companies and something about potentially more deals ...but not clear enough to get it written down correctly ......I wonder with the Sam connection are Immunocore and Adaptimmune looking in hmm